Page 21 - Pathogen Readiness News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HMS Professor of Pathology, Brigham and Women’s Hospital Core Faculty-Wyss Institute   HM News: One year in, where do we stand with diagnostics compared to where we were last year? Walt: There’s been a huge amount of progress with diagnostics. At the beginning, what the public and perhaps many in the field didn’t fully realize was the gargantuan amount of testing that’s required to keep a global pandemic in check. We needed on the order of three times the total installed diagnostic testing capacity in the world at the time. There were a lot of frustrations with respect to how fast th...

By RACHEL LEESON | Ragon Institute Communications Image: NiseriN/iStock/Getty Images Plus This article is part of Harvard Medical School’s of medicine, biomedical research, medical education, and policy related to the SARS-CoV-2 pandemic and the disease COVID-19. Does an infection with SARS-CoV-2 render people protected from subsequent infections with the virus? And if so, how do we know which individuals have built up their immune defenses? These have been two of the most important, and confounding, questions about COVID-19,  and the answers hold valuable clues about t...

New gene-based vaccine strategy receives grant from the Bill & Melinda Gates Foundation The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation. The grant will aid the effort to bring further preclinical validation to the AAV vaccine platform. An AAVCOVID vaccine candidate is set to enter clinical trials in 2021. The AAVCOVID vaccine program was founded at Mass General Brigham at the outset of the pandemic. Preliminary tests of the vaccines' stab...

 E-Mail The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation. The grant will aid the effort to bring further preclinical validation to the AAV vaccine platform. An AAVCOVID vaccine candidate is set to enter clinical trials in 2021. The AAVCOVID vaccine program was founded at Mass General Brigham at the outset of the pandemic. Preliminary tests of the vaccines' stability and potency at different temperatures revealed that AAVCOVID candidat...

What if scientists knew exactly what impact the SARS-CoV-2 virus had inside our lung cells, within the first few hours of being infected? Could they use...